Inventera Pharmaceuticals

About Inventera Pharmaceuticals

Inventera is a South Korean biotechnology company specializing in the development of innovative imaging diagnostic contrast agents. Founded in November 2018 by CEO Dr. Tae-Hyun Shin, who holds a Ph.D. in chemistry, the company leverages its proprietary nanomedicine platform, Invinity™, to create first-in-class products aimed at overcoming the limitations of existing MRI contrast agents. The company's origins trace back to a core nanomedicine invention developed in 2013. Inventera's business model is focused on the research, development, and commercialization of its pipeline products. The company's lead product, INV-002, is a musculoskeletal contrast agent for MR arthrography. As of early 2025, it had completed a Phase 2b clinical trial in Korea and received U.S. FDA clearance for a Phase 2b trial. The second key pipeline product is INV-001, a lymphovascular contrast agent for MR lymphangiography, which has demonstrated prolonged enhancement without the venous contamination often seen with conventional agents. The company is also developing INV-003 for pancreatic and biliary duct imaging. Inventera aims for commercialization of INV-002 by 2027. The company collaborates with strategic partners for manufacturing and distribution. A significant partnership was formed with LG Chem for the contract manufacturing of active pharmaceutical ingredients (APIs) for both clinical and commercial supply. Additionally, Inventera has an agreement with DongKook Life Science for R&D investment and exclusive distribution rights for its contrast agents. After raising 18.5 billion won in a Series C round in late 2024, Inventera was listed on the KOSDAQ exchange in April 2026. The company has built a systematic patent portfolio to protect its core technologies in major global markets, including the U.S., Europe, and Japan.